scispace - formally typeset
Search or ask a question
Institution

University of Alabama at Birmingham

EducationBirmingham, Alabama, United States
About: University of Alabama at Birmingham is a education organization based out in Birmingham, Alabama, United States. It is known for research contribution in the topics: Population & Medicine. The organization has 38523 authors who have published 86775 publications receiving 3930642 citations. The organization is also known as: UAB & The University of Alabama at Birmingham.


Papers
More filters
Journal ArticleDOI
TL;DR: The results show that numerous genes, some with known immune-related functions, predispose to SLE, and evidence of association with replication is found at FCGR2A, PTPN22 and STAT4, regions previously associated with SLE and other autoimmune diseases.
Abstract: Systemic lupus erythematosus (SLE) is a common systemic autoimmune disease with complex etiology but strong clustering in families (lambda(S) = approximately 30). We performed a genome-wide association scan using 317,501 SNPs in 720 women of European ancestry with SLE and in 2,337 controls, and we genotyped consistently associated SNPs in two additional independent sample sets totaling 1,846 affected women and 1,825 controls. Aside from the expected strong association between SLE and the HLA region on chromosome 6p21 and the previously confirmed non-HLA locus IRF5 on chromosome 7q32, we found evidence of association with replication (1.1 x 10(-7) or =9 other loci (P < 2 x 10(-7)). Our results show that numerous genes, some with known immune-related functions, predispose to SLE.

1,253 citations

Journal ArticleDOI
TL;DR: The neurocognitive changes observed in normal aging are described, followed by a description of the structural and functional alterations seen in aging brains.

1,253 citations

Journal ArticleDOI
TL;DR: Hyperfractionation and accelerated fractionation with concomitant boost are more efficacious than standard fractionation for locally advanced head and neck cancer.
Abstract: Purpose: The optimal fractionation schedule for radiotherapy of head and neck cancer has been controversial. The objective of this randomized trial was to test the efficacy of hyperfractionation and two types of accelerated fractionation individually against standard fractionation. Methods and Materials: Patients with locally advanced head and neck cancer were randomly assigned to receive radiotherapy delivered with: 1) standard fractionation at 2 Gy/fraction/day, 5 days/week, to 70 Gy/35 fractions/7 weeks; 2) hyperfractionation at 1.2 Gy/fraction, twice daily, 5 days/week to 81.6 Gy/68 fractions/7 weeks; 3) accelerated fractionation with split at 1.6 Gy/fraction, twice daily, 5 days/week, to 67.2 Gy/42 fractions/6 weeks including a 2-week rest after 38.4 Gy; or 4) accelerated fractionation with concomitant boost at 1.8 Gy/fraction/day, 5 days/week and 1.5 Gy/fraction/day to a boost field as a second daily treatment for the last 12 treatment days to 72 Gy/42 fractions/6 weeks. Of the 1113 patients entered, 1073 patients were analyzable for outcome. The median follow-up was 23 months for all analyzable patients and 41.2 months for patients alive. Results: Patients treated with hyperfractionation and accelerated fractionation with concomitant boost had significantly better local-regional control (p = 0.045 and p = 0.050 respectively) than those treated with standard fractionation. There was also a trend toward improved disease-free survival (p = 0.067 and p = 0.054 respectively) although the difference in overall survival was not significant. Patients treated with accelerated fractionation with split had similar outcome to those treated with standard fractionation. All three altered fractionation groups had significantly greater acute side effects compared to standard fractionation. However, there was no significant increase of late effects. Conclusions: Hyperfractionation and accelerated fractionation with concomitant boost are more efficacious than standard fractionation for locally advanced head and neck cancer. Acute but not late effects are also increased.

1,246 citations

Journal ArticleDOI
01 Jul 1995-Immunity
TL;DR: Data demonstrating that CD28 costimulation enhances the in vitro survival of activated T cells and suggesting that an important role of CD28costimulation is to augment T cell survival during antigen activation is suggested.

1,245 citations

Journal ArticleDOI
TL;DR: In this paper, HDL has been shown to have anti-atherogenic properties, which may explain the ability of HDL to promote the efflux of cholesterol from cells in the artery wall.
Abstract: There are several well-documented functions of high-density lipoprotein (HDL) that may explain the ability of these lipoproteins to protect against atherosclerosis. The best recognized of these is the ability of HDL to promote the efflux of cholesterol from cells. This process may minimize the accumulation of foam cells in the artery wall. However, HDL has additional properties that may also be antiatherogenic. For example, HDL is an effective antioxidants. The major proteins of HDL, apoA-I and apoA-II, as well as other proteins such as paraoxonase that cotransport with HDL in plasma, are well-known to have antioxidant properties. As a consequence, HDL has the capacity to inhibit the oxidative modification of low-density lipoprotein (LDL) in a process that reduces the atherogenicity of these lipoproteins. HDL also possesses other antiinflammatory properties. By virtue of their ability to inhibit the expression of adhesion molecules in endothelial cells, they reduce the recruitment of blood monocytes into the artery wall. These antioxidant and antiinflammatory properties of HDL may be as important as its cholesterol efflux function in terms of protecting against the development of atherosclerosis.

1,241 citations


Authors

Showing all 38940 results

NameH-indexPapersCitations
Rudolf Jaenisch206606178436
Joel Schwartz1831149109985
Tadamitsu Kishimoto1811067130860
Jasvinder A. Singh1762382223370
Gregg L. Semenza168502130316
David R. Jacobs1651262113892
Hua Zhang1631503116769
David R. Holmes1611624114187
David Cella1561258106402
Elaine S. Jaffe156828112412
Michael A. Matthay15199898687
Lawrence Corey14677378105
Barton F. Haynes14491179014
Douglas D. Richman14263382806
Kjell Fuxe142147989846
Network Information
Related Institutions (5)
University of Pittsburgh
201K papers, 9.6M citations

98% related

University of California, San Francisco
186.2K papers, 12M citations

98% related

National Institutes of Health
297.8K papers, 21.3M citations

97% related

Brigham and Women's Hospital
110.5K papers, 6.8M citations

97% related

University of North Carolina at Chapel Hill
185.3K papers, 9.9M citations

97% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
2023168
2022530
20215,327
20205,028
20194,402
20184,083